Synlogic

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Synlogic sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Synlogic: 10 sponsored US clinical trials, none currently recruiting.

Synlogic sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 2 trials.

Top-decile sponsor footprint

Synlogic ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 14/100

7 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

TERMINATED Phase 3

Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)

NCT05764239
COMPLETED Phase 1

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

NCT05462132
COMPLETED Early Phase 1

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

NCT05377112
COMPLETED Phase 1

Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers

NCT04984525
COMPLETED Phase 1

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT04629170
COMPLETED Phase 2

Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria

NCT04534842
TERMINATED Phase 1

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

NCT04167137
COMPLETED Phase 1

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT03516487
TERMINATED Phase 1

Safety, Tolerability and Pharmacodynamics of SYNB1020

NCT03447730
COMPLETED Phase 1

Safety and Tolerability of SYNB1020-CP-001

NCT03179878

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 1
Phase 3 1

Therapeutic Areas

Healthy 2
Enteric Hyperoxaluria 1

How the Synlogic early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 7 completed (70%).

Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Healthy (2 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Synlogic: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Synlogic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share SynlogicAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Synlogic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Synlogic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Synlogic page

10 registered trials is a research-attention snapshot, not an endorsement of Synlogic or any single study.

  • None of Synlogic's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Synlogic studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Synlogic pipeline card: 10 registered trials from official public datasets.Report a data error.